PD-1 and PD-L1 inhibitors

DelveInsight, the leading market research and consulting company has added a new report “Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016” to its portfolio.

The Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the client with details on the ongoing enterprises and the upcoming business opportunities related to new interventions. It comprehensively includes:

Information on 215+ products and 50+ different technologies along with 70+ companies actively involved in drug development. There are 5 drugs in phase III, 22 in phase II, 42 in phase I, and 87 in pre-clinical, 28 in discovery, 16 dormant and 19 discontinued drugs.

Brentuximab Vedotin,developed by Seattle Genetics, is the leading product.

R&D activities and technologies used along with the pipeline molecules in development.

DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications & Mechanism of Action (MOA). DelveInsight Report, PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2016 has received great response and feedback from clients.

PD-1and PDL-1 is the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent response in the increasing number of patients. Many experts say that out of all of the therapies, PD-1/PD-L1 inhibitors look to be the most promising in treating cancer.

Reports Highlights:

PD-1 and PD-L1 Inhibitors Therapy Pipeline scenario

Collaborations & partnering deals

Current Prominent Research Areas and Key Players

Pipeline product profiles PD-1 and PD-L1 Inhibitors Technologies

Market Drivers and Barriers

Report Coverage:

40+ products, 30+ companies and 15+ different technologies

PD-1/PDL-1 Inhibitors report provides the analysis on the worldwide therapeutic market of PD-1 and PD-L1 inhibitors. In addition, the report provides the development of combinations therapies with Immune-check point Inhibitors (PD-1 and PD-L1) along with the information on ongoing collaborations for the development of combinations regimens.

PD-1/PDL-1 Inhibitors report report covers the therapeutics assessment of pipeline molecules by mechanism of action (MoA),route of administration (RoA), molecule type, along with latest updates. The reports also cover Commercial Aspects such as the Current and Future Market, market drivers and barriers followed by SWOT Analysis

The Reports will help you to identify emerging players with potentially strong product information, licensing opportunities and helps you to create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 2,950 as a single user license, USD 5,900 as a site license andUSD 8,850 as a Global/Enterprise License.

For more information mail us atinfo@delveinsight.com

About Us:
DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

PD-1and PDL-1 are the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent response in the increasing number of patients. Many experts say that out of all of the therapies, PD-1/PD-L1 inhibitors look to be the most promising in treating cancer.

DelveInsight Report, “PD-1 and PD-L1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015” analyses that PD-1 and PD-L1 inhibitors are among the hottest and highly growing fields in biopharmaceutical industry. Most of these immunotherapeutic are being used in Oncology. According to the analysis, 34 drugs* are in pipeline. Focus of development is mainly on the antibody-based interventions targeting programmed cell death protein 1 (PD-1). Out of 34, 22* are in combination development with other therapeutics agents. Continuation of expansion of the combination regimens is likely to be one of the main themes surrounding immunotherapies as these partnerships are the key to developing competitively strong therapy regimens.

Future competitive landscape of PD-1 and PD-L1 inhibitors is estimated to be very strong. The market for PD-1 and PD-L1 drugs might be billions of dollars richer than many believe. These drugs which include Bristol-Myers’ Opdivo and Merck’s Keytruda, are going to be Blockbuster in upcoming years.

Scope of the Report

Overview of PD-1 and PD-L1 inhibitors, role, significance, pathway, mechanism of action (MoA) and biomarkers of PD-1 and PD-L1 inhibitors Indication wise detailed epidemiology along with trends in epidemiology, incidence and prevalence segmented in to major geographies

Report has covered the worldwide market of PD-1 and PD-L1 inhibitors, information of marketed molecules including along with patent expiry and impact on market after expiry and detail profiling of Pipeline assets

Key topics covered include strategic competitor assessment, market characterization, opportunities, barriers and challenges in the market along with SWOT analysis of the PD-1 and PD-L1 inhibitors market

Pipeline analysis: Comprehensive data split across different phases and emerging trends and comparative analysis of marketed and pipeline molecules, pipeline molecules with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with latest updates

Analysis of the current and future market competition in the global PD-1 and PD-L1 inhibitors drug market. Current scenario of market with upcoming blockbuster molecules and their impact on overall market.

Welcome!

We are Market Research & Business Consulting firm and serves as a Knowledge Partner across the value chain of Pharmaceutical Industry. Keep yourself updated with our blog. For more information visit www.delveinsight.com

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.